Take a deep dive into the business of transplantation!

Liver Transplant Financial Bootcamp

&

Kidney Transplant Financial Bootcamp

Co-located for 2019!

September 19–20, 2019

Loews Chicago O’Hare Hotel

Register at ASTS.org/bootcamps
Longitudinal Studies of a B Cell–Derived Signature of Tolerance in Renal Transplant Recipients


1Department of Surgery, Emory University, Atlanta, GA
2Immune Tolerance Network, Bethesda, MD
3Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA
4Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY
5Swedish Medical Center, Seattle, WA
6Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
7Departments of Medicine, and Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, NY
8Department of Surgery, University of Wisconsin, Madison, WI
* Corresponding authors: Laurence A. Turka, lturka@partners.org; Kenneth A. Newell, kanewell@emory.edu
† Current affiliation: MedImmune, Gaithersburg, MD
‡ Current affiliation: Department of Surgery, Duke University, Durham, NC
§ Current affiliation: Alexion Pharmaceuticals, Bellevue, WA

Biomarkers of transplant tolerance would enhance the safety and feasibility of clinical tolerance trials and potentially facilitate management of patients receiving immunosuppression. To this end, we examined blood from spontaneously tolerant renal transplant recipients and patients enrolled in two interventional tolerance trials using flow cytometry and gene expression profiling. Using a previously reported tolerant cohort as well as newly identified tolerant patients, we confirmed our previous finding that tolerance was associated with increased expression of B cell–associated genes relative to immunosuppressed patients. This was not accounted for merely by an increase in total B cell numbers, but was associated with the increased frequencies of transitional and naive B cells. Moreover, serial measurements of gene expression demonstrated that this pattern persisted over several years, although patients receiving immunosuppression also displayed an increase in the two most dominant tolerance-related B cell genes, IGKV1D-13 and IGLL-1, over time. Importantly, patients rendered tolerant via induction of transient mixed chimerism, and those weaned to minimal immunosuppression, showed similar increases in IGKV1D-13 as did spontaneously tolerant individuals. Collectively, these findings support the notion that alterations in B cells may be a common theme for tolerant kidney transplant recipients, and that it is a useful monitoring tool in prospective trials.

Abbreviations: BAFF, B cell–activating factor; BD, Becton, Dickinson and Company; cDNA, complementary DNA; FACS, fluorescence-activated cell sorting; HC, healthy control; ITN, Immune Tolerance Network; PBMC, peripheral blood mononuclear cell; PBS, phosphate-buffered saline; QGE, Quantitative Gene Expression; RIN, RNA integrity number; SI, standard immunosuppression; TOL, tolerant

Received 14 July 2014, revised 29 June 2015 and accepted for publication 07 July 2015

Introduction

Transplantation is the preferred treatment for appropriately selected patients with end-stage renal disease, as it confers a superior quality of life as well as a survival benefit relative to dialysis for the vast majority of affected individuals (1). However, transplantation is not a panacea as it is associated with significant risks and toxicities, primarily those accompanying the need for long-term immunosuppression. Registry data underscore the importance of these side effects, as cardiovascular disease, infection, and malignancy account for 60% of deaths in patients with functioning allografts after renal transplantation (United States Renal Data System: 2010 Annual Report, Vol 2, Chapter 7, http://www.usrds.org/atlas10.aspx). In addition to these concerns, calcineurin inhibitors, which form the backbone of most commonly used immunosuppressive regimens, are nephrotoxic, a side effect that likely contributes to both the premature failure of renal allografts and the development of end-stage renal disease in individuals who have received nonrenal transplants (2,3). Finally and perhaps most importantly, despite life-long administration of current immunosuppressive regimens, interstitial fibrosis and tubular atrophy continues to develop in a significant proportion of allograft recipients.
Transplantation tolerance, which we define here operationally as stable maintenance of good graft function for at least 1 year in the absence of immunosuppression in an immunocompetent individual, could, as has been recently reported, improve long-term outcomes following transplantation by minimizing or avoiding the side effects of maintenance immunosuppression (4,5). Tolerance to renal allografts has been achieved in small numbers of patients enrolled in early-phase clinical protocols; however, the applicability of these protocols to a broader population is limited at present (6–9). Development of reliable biomarkers of tolerance would not only greatly enhance the safety and feasibility of such protocols, but also potentially have a large impact on the care of transplant recipients treated with standard immunosuppressive drugs, as some of these transplant recipients may be candidates for minimization, and perhaps eventual withdrawal of, immunosuppression. To this end, several groups including our own have recently described biomarkers present in spontaneously tolerant kidney and liver transplant recipients following discontinuation of all immunosuppression (10–15). In the case of renal transplants, functionally tolerant recipients are characterized by increased numbers of B cells and overexpression of B cell–associated genes in their peripheral blood and urine (11,13,14). Interestingly, the increase in B cell numbers reflects a specific expansion of transitional B cells (14) and B cells that express inhibitory receptors (12), suggesting that these B cells may actively regulate the immune response to the transplanted kidney. This hypothesis is intriguing, given recent reports demonstrating the effects of regulatory B cells in experimental models of transplantation and autoimmunity (16–18).

In this article, we extend our previous observations from the Immune Tolerance Network (ITN) registry of tolerant renal transplant recipients in several important ways. First, we have analyzed additional tolerant recipients newly recruited to the registry and also have provided a substantially more extensive analysis of B cell subsets. Second, we demonstrate that the B cell–focused gene signature, indicating overexpression of selected B cell genes, is not simply a result of increased circulating total B cell numbers. A third important observation is that both cellular and gene expression changes noted in tolerant kidney transplant recipients, are, in large part, maintained over time. However, we also observed that the B cell–related genes that were highly associated with tolerance also increased with time in transplant recipients maintained on conventional immunosuppression, such that the differences between the groups diminished over time. Finally, we report that kidney transplant recipients developing tolerance as a result of a prospectively applied mixed chimerism protocol display the same B cell–related gene expression changes as observed in spontaneously tolerant kidney transplant recipients. Collectively, these findings support the notion that alterations in B cells may be a common theme for tolerant kidney transplant recipients, and could potentially provide a useful immune monitoring tool in prospective trials.

**Materials and Methods**

**Patients**

Patients enrolled under four separate ITN protocols are included in this analysis (see Table 1 for detailed demographic and clinical information and Table S1 for assays):

**ITN0507 (FACTOR):** This study is the ITN-sponsored renal transplant registry to identify pre-existing tolerant renal transplant recipients. Some of the patients enrolled under this protocol were initially studied in an earlier publication (14), with limited flow cytometric analysis, and without longitudinal sampling. Since publication of that study, we have identified and added seven new spontaneously tolerant patients who met the enrollment criteria for the study. Centers participating in enrollment are Emory University (Atlanta, GA), National Institutes of Health (Bethesda, MD), Swedish Medical Center (Seattle, WA), and University of Wisconsin (Madison, WI). The protocol was approved by the Institutional Review Board (IRB) of each participating center, and by a Data and Safety Monitoring Board convened by the National Institutes of Allergy and Infectious Diseases. Written informed consent was obtained from each patient. Specimens and clinical information were collected annually, with up to 3 years follow-up now available for the majority of participants.

Renal allograft recipients from ITN0507 were enrolled into two groups: tolerant (TOL; n = 39), defined as individuals who, for at least 1 year prior to enrollment, had not taken immunosuppressive medications and had stable renal function and serum creatinine within 25% of baseline (as evaluated by three experienced transplant physicians); and standard immunosuppression (SI; n = 38), defined as patients with clinically stable renal function (using the same criteria as TOL) while on a maintenance triple-drug immunosuppressive regimen (including a calcineurin or mechanistic target of rapamycin inhibitor, an antiproliferative agent, and corticosteroids). As published previously and shown in Table 1, most of the TOL patients received living related allografts and were well HLA matched. An additional group of normal healthy control (HC) participants (n = 42) with no known history of renal disease/dysfunction or evidence of acute medical illness was enrolled. Of these ITN0507 patients, we analyzed samples as follows: TOL = 32 (which includes 25 patients originally reported in this study plus seven newly identified tolerant patients), SI = 34, and HC = 15 (only for flow cytometry analysis). Note 20 more HC samples from an IRB-approved assay registry study were also included for flow cytometry analysis.

**ITN010 (formerly NKD03) and ITN036:** These were closely related studies of conditioning regimens designed to induce tolerance in recipients of primary live-donor one haplotype HLA-matched renal allografts using mixed chimerism induced by bone-marrow transplantation. The clinical outcomes of these patients have been reported previously (7,19).

**ITN013:** This was a study of CAMPATH-1H induction therapy with maintenance tacrolimus/sirolimus immunosuppression, followed by serial immunosuppression withdrawal in primary live donor one-haplotype or zero-mismatched deceased donor adult renal transplant recipients. The clinical outcomes of these patients have been reported (20).
### Table 1: Demographic and clinical characteristics

<table>
<thead>
<tr>
<th></th>
<th>ITN507 TOL (n=25)</th>
<th>New Tol (n=7)</th>
<th>ITN013 SI (n=34)</th>
<th>Sirolimus multi-agent (n=2)</th>
<th>ITN010 &amp; ITN036 TOL (n=7)</th>
<th>Return to SI (n=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Race, n</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black or African-American</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>24</td>
<td>7</td>
<td>29</td>
<td>7</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>American Indian or Alaska Native</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ethnicity, n</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>23</td>
<td>6</td>
<td>33</td>
<td>7</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td><strong>Sex, n</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10</td>
<td>4</td>
<td>15</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>3</td>
<td>19</td>
<td>5</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td><strong>Donor type, n</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Living-related</td>
<td>18</td>
<td>3</td>
<td>15</td>
<td>6</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Living-unrelated</td>
<td>1</td>
<td>3</td>
<td>9</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deceased donor</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age at enrollment, yrs, mean (SD)</strong></td>
<td>52 (11.5)</td>
<td>56 (7.2)</td>
<td>47 (12.8)</td>
<td>42 (10.2)</td>
<td>54 (1.1)</td>
<td>31 (10.6)</td>
</tr>
<tr>
<td><strong>Age at transplantation, yrs, mean (SD)</strong></td>
<td>31 (12.8)</td>
<td>36 (9.9)</td>
<td>37 (15.1)</td>
<td>42 (10.2)</td>
<td>54 (1.1)</td>
<td>31 (10.6)</td>
</tr>
<tr>
<td><strong>Interval between transplant and enrollment, yrs, mean (SD)</strong></td>
<td>21 (9.6)</td>
<td>20 (10.9)</td>
<td>10 (10.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Donor age, yrs, mean (SD)</td>
<td>52 (8.9)</td>
<td>52 (10.1)</td>
<td>53 (9.6)</td>
<td>45 (7.5)</td>
<td>43 (18.4)</td>
<td>50 (9.0)</td>
</tr>
<tr>
<td><strong>Primary cause for renal failure</strong>, n</td>
<td>Genetic</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etiology uncertain</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune mediated</td>
<td>13</td>
<td>1</td>
<td>18</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyelonephritis/interstitial nephritis</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Structural</td>
<td>3</td>
<td></td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HLA mismatch (A, B, and DR loci)</strong></td>
<td>Mean (SD)</td>
<td>1.1 (1.71)</td>
<td>2.3 (1.96)</td>
<td>3.3 (0.76)</td>
<td>3.2 (0.76)</td>
<td>2.3 (0.76)</td>
</tr>
<tr>
<td>Data missing, n</td>
<td>10</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Years off IS</strong>, yrs, mean (SD)</td>
<td>16 (10.4)</td>
<td>14 (17.1)</td>
<td>NA</td>
<td>5 (1.2)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Data missing, n</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reason for discontinuing IS, n</strong></td>
<td>Medical condition</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Noncompliance</td>
<td>20</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data missing</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Documented episodes of acute rejection, n</strong></td>
<td>No acute rejection</td>
<td>23</td>
<td>6</td>
<td>24</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Mild acute cellular rejection (Grade IA)</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Mild acute cellular rejection (Grade IB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate acute cellular rejection (Grade IIA)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Moderate acute cellular rejection (Grade IIB)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Renal function, mean (SD)</strong></td>
<td>Creatinine level, mg/dL</td>
<td>1.5 (1.77)</td>
<td>1.7 (0.56)</td>
<td>1.4 (0.46)</td>
<td>1.4 (0.29)</td>
<td>2.9 (0.07)</td>
</tr>
<tr>
<td>Proteinuria (&gt;30 mg/dL), n</td>
<td>&lt;30 mg/24 h</td>
<td>10</td>
<td>6</td>
<td>24</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>≥30 mg/24 h</td>
<td>20</td>
<td>6</td>
<td>28</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Data missing</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

TOL, tolerant; SI, standard immunosuppression; ITN, Immune Tolerance Network; HIV, human immunodeficiency virus; IS, immunosuppression.

1Two ITN507 TOL and three SI patients had multiple primary causes for renal failure.

2Allele or antigen level mismatch analysis was performed based on the resolution of available HLA data. Synonymous mutations were not considered mismatches.

3Unable to resolve one HLA-B mismatch; counted as a match.

4Unable to resolve one HLA-DRB mismatch; counted as a match.

5HLA-DR typing missing for one participant; this participant is analyzed on four present antigens.
Gene expression
Whole blood was collected in Tempus™ (ThermoFisher, Cambridge, MA) Blood tubes and isolated using the Applied Biosystems‘ PRISM™ (ThermoFisher) 6100 Nucleic Acid PrepStation. Samples and RNA were stored at –80°C and cDNA was generated at Expression Analysis. The MassARRAY QGE (Sequenom, San Diego, CA) multiplexed primer and competitive template designs and analysis were reported previously (14). All samples were run in a single batch. Over 94% of the samples had RNA integrity number (RIN) scores >6.0, and the small number of samples that had lower RIN scores did not display aberrant results.

Flow cytometric analysis
Previously frozen peripheral blood mononuclear cells were incubated in 1 mL of prewarmed complete media (RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM l-glutamine) containing 20 nM of MitoTracker Green (Invitrogen, Cambridge, MA) at 37°C for 30 min. Cells were collected by centrifugation then resuspended in 10 μL of warm complete medium and incubated at 37°C for 30 min. Next, the cells were stained on ice for 30 min in 100 μL fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered saline (PBS) + 0.5% bovine serum albumin) containing 5% normal mouse serum, 5% normal rat serum, and the following fluorochrome-conjugated mouse anti-human monoclonal antibodies: PE-IgD (I6A2, Becton-Dickinson and Company (BD) Biosciences), PE-A610-CD24 (SN3, Invitrogen), PE-Cy5-CD21 (B-ly4, BD), PerCP-Cy5.5-CD38 (HIT2, BD), PE-Cy7-CD23 (EBV-CS2, eBioscience), Pacific Blue-CD3 (SP34-2, BD), Qdot605-CD27 (CLB-271, Invitrogen), allophycocyanin-CD95 (DX2, BD), allophycocyanin-Cy7-CD19 (SJ25C1, BD Biosciences), as well as the biotinylated 9G4 rat anti-human Ig idiotype antibody, which was detected by a further staining with 100 μL of streptavidin-Alexa680 (Invitrogen) at a 1:500 dilution in FACS buffer on ice for 30 min. Cells were washed with 3 mL PBS and stained with 1 mL LIVE/DEAD aqua-fluorescent reactive dye (Invitrogen) at a 1:1000 dilution in PBS on ice for 30 min. After resuspension in FACS buffer, cells were acquired on a LSRII flow cytometer (BD Biosciences) and analyzed with Tree Star software (Flow Jo, Ashland, OR).

Measurements of BAFF level
B cell–activating factor (BAFF) assays were performed by Aushon Biosystems (www.aushonbiosystems.com; Billerica, MA).

Statistical analysis
For flow cytometry data, sample group differences for each B cell subset (as a fraction of CD19+ cells) were identified using a one-way analysis of variance, followed by pairwise comparisons between groups with multiple testing correction (Tukey–Kramer method). Unsupervised, hierarchical clustering of B cell profiles was accomplished using complete linkage and Euclidean distance applied to centered log-ratio transformed frequency data (“Aitchison distance”) (21) and was performed using Matlab (The Mathworks Inc., Natick, MA). MassArray QGE (Sequenom) data were normalized to housekeeping genes (GAPDH, UBC, and YWHAZ) and log2 normalized. All gene expression visualizations and t-tests for group comparisons were performed in the R statistical programming language. Hierarchical clustering for MassArray QGE data were generated based on Euclidian distance. All figures, data, and programming code associated with this work can be found on the ITN data-sharing portal: www.itntrialshare.org.

Results

Increased naive/transitional and decreased memory B cells in tolerant renal allograft recipients
We and others reported previously that spontaneously tolerant renal transplant recipients had increased numbers of peripheral blood B cells compared with a group of patients displaying stable function while receiving standard immunosuppression (12–14). Moreover, there was a consistently observed increase in the percentage of immature/transitional B cells, defined as CD19+CD38−CD24+ IgD+. To extend this analysis further, we performed more detailed multiparameter flow cytometry in both the previously studied group of patients, as well as six newly identified spontaneously tolerant renal allograft recipients. As shown by the example in Figure 1, we defined four canonical B cell subsets using IgD and CD27 as markers: switched memory, IgD−CD27−; unswitched memory, IgD+CD27−; double negative memory, IgD+CD27+; and IgD−CD27+ subset. The IgD−CD27− subset contains both naïve and transitional B cells and can be further divided into T1 + T2, T3, and naïve subsets based on MitoTracker Green extrusion and CD24/CD38 expression as follows: naïve, IgD−CD27−MTG−; T3, IgD+CD27+MTG+CD24−/−CD38+; and T1 + T2, IgD−CD27+MTG+CD24−+CD38−+ (22,23).

Tolerant recipients had significantly increased frequencies of total B cells, and T1 + T2 early transitional B cells and naïve B cells compared with stable patients on standard immunosuppression. Conversely, the tolerant patients had significantly decreased numbers of both switched and unswitched memory B cells (Figure 2). It should be noted that in our earlier report on tolerant patients (14), staining was done on fresh whole blood, and the results were reported as absolute cell counts per microliter of whole blood. This analysis showed that memory B cells were present in higher absolute numbers in tolerant participants than in patients on standard immunosuppression, because tolerant patients had much higher total B cell counts. In that study, as in the current analysis (done on frozen cells, which does not allow for determination of absolute cell numbers), the percentage of memory B cells within the total B cell population is lower in tolerant patients. The fact that the naïve B cell frequency decreases while the memory B cell frequency increases in participants on standard immunosuppression suggests that we are not observing a generalized nonspecific decrease in B cells caused by immunosuppression, but that tolerance and/or SI therapy may have disparate effects on different B cell subsets. Consistent with our previous results, tolerant recipients were very similar to the group of healthy controls, with the only significant difference between the healthy controls and tolerant patients being that the tolerant group had a lower frequency of unswitched memory cells than did healthy controls.

An unsupervised hierarchical cluster analysis based on B cell profiles yielded three primary clusters and one singleton (Figure 3A). One cluster comprised predominantly tolerant patients and healthy controls (with a small number of patients on standard immunosuppression). A second cluster contained primarily healthy controls and patients on standard therapy, and the third (and smallest) cluster had only patients on immunosuppression. We also constructed a stacked bar plot of memory and transitional B cell subset frequencies ordered on the single parameter of peripheral
B cell percentage (%CD19+ cells in the total lymphocyte gate; Figure 3B). There appears to be a relatively greater “mixing” of the tolerant patients among the other cohorts in this type of analysis, suggesting that in addition to the number of B cells, their maturational status also may correlate with the tolerant state. While clearly only limited conclusions can be drawn from this type of analysis, combined with the data in Figure 2, it suggests that tolerant patients may differ from healthy controls, and confirms the presence of a B cell, and B cell subset, bias, in tolerant patients. Of note, we found no significant correlation between time posttransplant and B cell number in either tolerant or drug-treated patients ($p = 0.33$ and $p = 0.51$, respectively).

**BAFF**, a member of the tumor necrosis factor superfamily expressed in multiple cell types, plays an important role in the proliferation and maturation of transitional B cells and the subsequent survival of mature B cells and plasma cells (24). As increased levels of circulating BAFF could explain the increase in B cell numbers observed in tolerant patients, we measured BAFF levels in the serum of our patients from blood draws obtained at the same time points as for B cell analyses. As shown in Figure 4, increased numbers of B cells were not the result of alterations in BAFF levels. Indeed, when normalized for B cell numbers, patients on standard immunosuppression had higher levels of BAFF, perhaps due to lower B cell counts in that cohort.

**B cell biased gene expression profiles in tolerant renal transplant recipients**

In an earlier article (14), we reported that overexpression of 31 genes, 26 of which were specific to B cells, distinguished tolerant renal transplant recipients from patients who were receiving immunosuppression. Notably, a linear discriminant analysis algorithm utilizing three of the most highly differentially expressed genes identified in a training set (IGKV1D-13, IGKV4-1, and IGLL-1) was able to accurately predict the status of patients (tolerant vs. stable on immunosuppression) with a high degree of accuracy in a very small test cohort of patients ($n = 12$). In that study, differentially expressed genes were initially identified by microarray and were subsequently assessed by polymerase chain reaction using the Sequenom methodology. Retesting of the original samples (Figure S1) revealed that
while the actual numbers of detected mRNA molecules were 30–100 times lower in the repeat assay compared with the original study, differences in the expression of the two genes (IGKV1D-13 and IGLL-1) that most “robustly” differentiated tolerant patients from those receiving immunosuppression in the original study remained significantly different (\(p < 0.001\) and \(p < 0.05\), respectively). In contrast, the expression levels of the third gene, IGKV4-1, were no longer different between the groups.

Importantly, transcript levels of the single most predictive gene, IGKV1D-13, did not merely reflect alterations in B cell numbers as even after correcting for total B cells, a significant difference in transcript numbers remained (Figure 5). However, we did find that after normalization for naïve and transitional B cell numbers, while a difference remained between tolerant and drug-treated patients, it was not statistically significant (Figure 5). This suggests that although the naïve and/or transitional B cell compartments contribute to some portion of the altered gene expression seen in tolerant patients, the gene expression levels also differ on a per cell basis or that other cell subsets contribute as well.

In addition to our focused analysis of the three genes originally reported to be robust predictors of clinical tolerance, we also took the opportunity of having recruited new patients to the tolerance registry to examine the expression of the 232 genes shown in Tables S2 and S3 using Sequenom methodology. These genes were selected based on our original microarray data (14) as well as genes that had been reported by others to be associated with tolerance. As shown in Figure S2, 15 of the top 20 genes differentially expressed between tolerant and standard immunotherapy participants were B cell specific, confirming our findings that B cells and B cell–expressed genes are preferentially represented in drug-free tolerant kidney transplant recipients. While these additional genes are potentially of interest, IGKV1-D13 and IGLL-1 remain the most discriminating markers.

**Longitudinal IGKV1D-13 and IGLL-1 expression in the ITN registry**

Biomarkers of tolerance should be stable over time. In the case of transplantation tolerance, changes in any putative biomarker should occur only with the loss of the tolerant phenotype. We examined the stability of IGKV1D-13 and IGLL-1 expression over time in both tolerant individuals and those continuing to receive immunosuppression. As displayed in Figure 6, at the population level (panel A) and the individual level (panel B), the expression of IGKV1D-13 and IGLL-1 remained relatively stable over time in tolerant patients. Interestingly, the expression of IGKV1D-13 and IGLL-1 tended to increase over time in the cohort of patients receiving immunosuppression, as a result of which, the difference between IGKV1D-13 and IGLL-1 expression in tolerant versus standard immunosuppression lost statistical significance (Figure 6A). Whether this relates to changes in immunosuppressive agents, the development of pro-tolerance immune mechanisms in immunosuppressed patients, or is a simple function of time following transplantation remain to be determined.
Previously we have reported on two patient cohorts enrolled in ITN-sponsored trials designed to induce tolerance in renal transplant recipients. In ITN010 and ITN036, transient mixed hematopoietic chimerism was induced by donor bone marrow transplantation in conjunction with a nonmyeloablative conditioning regimen. Seven of 10 patients enrolled were tolerant for at least 5 years with excellent graft function. In ITN013 (20), 10 patients were treated with CAMPATH-1H, followed by tacrolimus plus sirolimus, with the intention of withdrawing immunosuppression by 2 years.

**IGKV1D-13 expression in patients enrolled in prospective interventional tolerance trials**

Previously we have reported on two patient cohorts enrolled in ITN-sponsored trials designed to induce tolerance in renal transplant recipients. In ITN010 and ITN036, transient mixed hematopoietic chimerism was induced by donor bone marrow transplantation in conjunction with a nonmyeloablative conditioning regimen. Seven of 10 patients enrolled were tolerant for at least 5 years with excellent graft function. In ITN013 (20), 10 patients were treated with CAMPATH-1H, followed by tacrolimus plus sirolimus, with the intention of withdrawing immunosuppression by 2 years.

**Figure 3:** (A) Clustered, stacked bar plot of memory and transitional B cell subset frequencies comprising a six-part composition. Each column of data is derived from a single sample from one of four sample groups (indicated by a symbol above each column). Each color represents the proportion of a particular cell subset in the sample (of CD19⁺ cells). The percentages of CD19⁺ (of lymphocytes) are shown beneath the stacked bar plot. Eighty-eight B cell profiles are hierarchically clustered (see Materials and Methods) resulting in three clusters and a singleton. (B) Same as (A) except samples are ordered by the percentages of CD19⁺ cells in the lymphocyte gate. https://www.itntrialshare.org/FACTOR_fig3.url. SM, switched memory; DN, double negative memory; USM, unswitched memory; T1 + T2, transitional type 1 and type 2; T3, transitional type 3; N, naïve; HC, healthy control; SI, standard immunosuppression; TOL, tolerant.
in individuals meeting eligibility criteria. Ultimately, eight of the 10 were weaned down to sirolimus monotherapy.

We compared IGKV1D-13 expression levels in “spontaneously” tolerant patients (ITN507, using the first available samples) with patients enrolled in the interventional trials above (ITN010, ITN036, and ITN013) (Figure 7). In the latter studies, samples were obtained from the mixed chimerism patients at 12 months posttransplant, and for the CAMPATH-1H-treated patients at 48 months posttransplant, times at which lymphoid reconstitution was complete and B cell numbers had returned to baseline levels.

A number of findings emerge from this analysis. First, IGKV1D-13 expression levels in the five new patients recruited into the registry for whom expression data were available are indistinguishable from those originally reported (14), further confirming the validity of this finding. Second, in the combined bone marrow and kidney transplantation trials (ITN010 and ITN036), the expression of IGKV1D-13 in the seven patients who were operationally tolerant was indistinguishable from spontaneously tolerant patients in the ITN registry (ITN507). Also of note is that while three of the seven operationally tolerant patients eventually required reinstition of immunosuppression...
(two with clinical and histologic features of chronic alloimmune-mediated graft injury and one for recurrence of membranoproliferative glomerulonephritis), their IGKV1D-13 expression at early time points when they displayed operational tolerance is similar to that of the other four who remain tolerant (light blue circle symbols in Figure 7). Unfortunately, as there are no samples available at later time points, we cannot determine whether IGKV1D-13 expression was altered at the time tolerance was lost. Third, although only a single sample was available from a patient who experienced early acute rejection and consequently returned to maintenance immunosuppression, the expression of IGKV1D-13 (at the time that patient was on drug therapy) was similar to ITN registry patients who displayed stable renal function while receiving immunosuppression.

Interpretation of the data from ITN013 is complex. As noted above, eight of the 10 patients were weaned to sirolimus monotherapy (samples were available from seven of these eight patients). Three of these seven met the criteria for sirolimus withdrawal, which included reduction of sirolimus to a dose of 1 mg/day, the absence of donor-specific antibody (DSA), and a protocol biopsy that showed no deposition of C4d; however, the patients elected to remain on this low dose of sirolimus for nonimmunologic reasons. The other four patients all had DSA, with one patient also showing C4d deposition on a biopsy. These

---

**Figure 6: Longitudinal IGKV1D-13 and IGLL-1 expression.** (A) Scatter plots for normalized IGKV1D-13 and IGLL-1 expression in all available samples. The time points indicate the point at which the sample was obtained relative to the start of the study (i.e., year 0 is the first blood sample we obtained, year 1 is 1 year later, etc.). Mean values for each group at each time point are represented by * and connected by dashed lines. P-values represent comparisons between the groups at each time point. NS, not significant. (B) Longitudinal IGKV1D-13 expression as a function of months posttransplant. Tolerant patients (TOL) are shown in blue, and patients on standard immunosuppressive therapy (SI) are shown in red. Points joined by a line depict sequential samples from the same participant. Arrows indicate four patients who were operationally tolerant when first studied, but later went back on immunosuppressive therapy. https://www.itntrialshare.org/FACTOR_fig6A.url https://www.itntrialshare.org/FACTOR_fig6B.url.
four individuals were not considered eligible for drug withdrawal. The remaining two patients in the trial were converted from sirolimus to tacrolimus and mycophenolate at ~12–24 months due to development of DSA and biopsies showing both histologic evidence of alloimmune injury (Banff grade IIA and borderline) and positive C4d staining (focally positive and diffusely positive).

We observed that the two patients on tacrolimus plus mycophenolate had the lowest levels of IGKV1D-13 at 48 months posttransplant (albeit still higher than most ITN507 patients on standard immunosuppression), while the seven on sirolimus monotherapy had levels of IGKV1D-13 expression similar to tolerant patients. This point is particularly important and indicates that low levels of IGKV1D-13 expression seen in our previous cohort of stable drug-treated allograft recipients are unlikely to be an artifact of immunosuppression per se, although the influence of the level and/or type of immunosuppression used remains to be determined. Of note, however, among the seven sirolimus monotherapy patients, the three who were DSA-/C4d– had indistinguishable IGKV1D-13 levels from the four who were DSA+/C4d+ (data not shown).

Discussion

The goal of this study was to further explore the association between B cells and tolerance following renal transplantation. Key aspects of our work include (1) a detailed phenotypic analysis of B cell subsets; (2) longitudinal data on the expression of key B cell genes in patients who are operationally tolerant as well as those who are stable on immunosuppression; and (3) analysis of relevant B cell genes in patients from two different tolerance-induction studies.

Our data confirm previous findings from our group and others showing that renal transplant recipients displaying “spontaneous” operational tolerance (i.e., patients who were not enrolled in tolerance protocols) are distinguished from recipients maintained on immunosuppression by increased numbers of B cells in the blood as well as the increased expression of selected B cell–associated genes in peripheral blood mononuclear cells (25). Beyond simple increases in B cell numbers, the B cell population in the tolerant patients was characterized by an increased prevalence of transitional and naïve B cells, and reciprocal decreases in both switched and unswitched memory B cells. Recent studies support a role for transitional B cells in renal allograft tolerance. Chesneau et al demonstrated that tolerant recipients had an elevated frequency of transitional and naïve B cells and a decreased frequency of plasma cells, and moreover that B cells from tolerant patients produced more IL-10 and were less likely to differentiate into plasma cells in vitro than did B cells from patients receiving immunosuppression (26). These investigators have also found that B cells from tolerant recipients

Figure 7: Cross-sectional IGKV1D-13 expression in renal transplant recipients enrolled in multiple Immune Tolerance Network (ITN) studies. ITN507 is the tolerant renal transplant registry (TOL n = 19; New-TOL n = 5; standard immunosuppression [SI] n = 25); ITN010 and 036 are the mixed chimerism trials with combined bone marrow and renal transplants. Samples from seven operationally tolerant patients (TOL) were collected 0.33–7 years after discontinuation of immunosuppression (no differences in IGKV1D-13 expression were seen in relation to time, not shown). The three patients who eventually had to restart immunosuppression are indicated by light blue circles. One patient who was returned to SI (Return to SI) had their sample obtained 1 year after transplantation (which was 2 months after the patient rejected and was returned to immunosuppression). ITN013 is the Campath-1H followed by tacrolimus plus sirolimus trial where samples were obtained 4 years after transplantation. In ITN013, seven patients were weaned and stable on sirolimus monotherapy (Sirolimus Mono), while two patients required re-institution of tacrolimus plus mycophenolate (SI Multiagent). https://www.itntrialshare.org/FACTOR_fig7.url.
can suppress effector T cell responses in vitro in a
granzyme B–dependent fashion (27). Finally, it is intriguing
that the intentional depletion of B cells using rituximab at
the time of renal transplantation may result in high rates of
acute rejection in patients receiving a conventional
immunosuppressive regimen (28). When taken in aggregate,
data from experimental transplant models, clinical
transplantation, and our studies of tolerance following renal
transplantation all suggest that B cells may play a functional
role in suppressing alloimmunity (16,29–32).

As part of the current study, we conducted additional
analyses of gene expression in both newly identified as well
as previously identified tolerant kidney transplant recipi-
ents. As might be predicted, expression of selected B cell–
associated genes by newly identified tolerant recipients
was indistinguishable from that of the previously studied
individuals. Importantly, however, we now have a longitudi-
nal analysis of gene expression in our patient cohorts, and
find that the increased level of expression of the most
predictive differentially expressed B cell–related genes,
IGKV1D-13 and IGLL-1, remained stable over a period of
3 years in the cohort of tolerant recipients for whom serial
samples were available.

We are aware of only a single prior longitudinal study of
biomarkers of clinical tolerance following kidney transplan-
tation (33). In that article, two samples separated by 0.8 to
4 years in time from each of four tolerant kidney transplant
recipients showed stable increases in the number of CD19+
cells in the peripheral blood as well as stable increases in
the B cell–associated genes CD19, CD20, and Bank1.
Notably, our data show that overexpression of selected
B cell genes is not simply a result of increased circulating
B cell numbers; much of the perturbation in B cells
associated with clinical tolerance appears to be related to
the expansion of T1 and T2 transitional B cells and the
contraction of memory B cells. We speculate that the
increased B cell transcripts we detect in peripheral blood
are a result of their overexpression by immature/transitional
B cells. Although we were unable to do so in the current
study, this could be directly tested by determining the gene
expression profiles of freshly sorted transitional B cells
from patients and healthy controls.

It is important to note that transplant patients stable on
immunosuppression had increases in both IGKV1D-13
and IGLL-1 over time, to the extent that by 3 years after
the first entry into the registry, the differences in these
parameters between this cohort and the tolerant cohort
were no longer statistically significant. Increases in the
expression of B cell–related genes over time in the cohort of
patients receiving immunosuppression may not be entirely
unexpected. In liver transplant recipients, one of the most
powerful predictors of the tolerant phenotype is time since
transplantation (34). While the mechanisms of tolerance
induction appear to be different following liver and kidney
transplantation, it is conceivable that over time the immune
system undergoes adaptations that favor immune toler-
ance to the transplanted kidney. The increase in B cell–
related genes seen over time in at least some patients with
stable function who are receiving immunosuppression may
be consistent with a model of acquired tolerance that is
more prevalent in kidney transplantation than previously
appreciated. As well, we cannot exclude the possibility that
changes over time (most likely reductions) in doses of
immunosuppression may contribute to alterations in B cell
profiles and/or B cell–expressed genes.

One factor confounding our analysis is that the time since
transplantation was much greater for the tolerant cohort
than for the group of patients still receiving immuno-
suppressant. This raises the possibility that the increase in
B cells observed in the tolerant cohort simply reflects the
immune system’s adaptation to the transplanted allograft
or that B cell synthesis eventually recovers as immunosup-
pression is tapered over time in many patients. This notion
is also consistent with our finding that the peripheral
expression of B cell–related genes increases with time
following transplantation even for those patients continuing
to receive immunosuppression.

Among the most important results reported in this study are
the data on patients enrolled in tolerance-induction proto-
cols. We found that patients who were tolerant following a
protocol of thymic irradiation, nonmyeloablative condition-
ing, and combined bone marrow and kidney transplantation
had levels of B cell–related gene expression that were
similar to our spontaneously tolerant cohort. Of further
note, the sole patient treated with this protocol who lost
tolerance had levels of B cell–related gene expression (at a
time when he/she was returned to immunosuppression)
that were similar to patients in the current study who had
been maintained on immunosuppression. These findings
suggest that patients developing tolerance either sponta-
neously or as a result of purposeful perturbation of the
immune system may share similar markers, or perhaps
even mechanisms, of tolerance.

In this vein, the patients in ITN013 also are informative as
they displayed increased expression of selected B cell–
associated genes at a time when they remained stable on
low-dose sirolimus-based immunosuppression. This im-
plies that the association of increased B cells numbers
and gene expression seen in tolerance may not solely be
the result of the absence of immunosuppression, albeit the
numbers of patients in this study are small, and perhaps
more notably, all were on single agent sirolimus. However,
also arguing against a simple drug effect is the observation
that tolerant liver transplant recipients do not show
the same increase in B cells relative to those receiving
immunosuppression as do tolerant kidney transplant
recipients (33). The generalizability of these findings to
larger numbers of renal allograft recipients, including those
on multidrug immunosuppressive regimens, is under active
investigation.
A cautionary finding from our analysis of the patients enrolled in ITN013 that requires further study is the observation that four of the seven patients on sirolimus monotherapy, all of whom had high expression of IGKV1D-13, also had detectable DSA and in one case, a biopsy that was C4d⁺. While the demonstration of donor-specific humoral sensitization is generally incompatible with the tolerant phenotype, in rare instances, DSA has been reported in individuals meeting the definition of operational tolerance, highlighting both the limitations of how clinical tolerance is defined and our understanding of the pathogenic impact of different types of DSA (35). Nonetheless, current clinical practice would preclude drug minimization in the face of a positive DSA and thus any proposed tolerance signature that was observed in DSA⁺ patients would have to be interpreted with great care.

While several groups including our own have demonstrated an association between B cells and renal allograft tolerance, other cell populations have been implicated as well, including myeloid-derived dendritic cells and regulatory T cells (36,37). Although it is not yet possible to integrate these various findings into a comprehensive model describing the development of tolerance, these data suggest that factors beyond B cells alone are likely to play an important role.

A final consideration is how these findings may be applied to clinical transplantation. It has recently been suggested that the association of B cells with tolerance following kidney transplantation is robust enough to warrant clinical trials using markers related to B cells to guide the minimization of immunosuppression (38). Several factors must be addressed in contemplating trials of this type including safety, defining an appropriate control group, and their feasibility. Despite the theoretical importance for an individual of having a tool to detect or predict tolerance, it is self-apparent that if the frequency of tolerance is vanishingly low, such a tool will have a very limited impact on the field as a whole. A previous report indicated that only 3.5% of 144 renal transplant recipients with a stable clinical status at 5 or more years following transplantation displayed a B cell-based gene expression profile that was consistent with the tolerant phenotype (11). In addition, it is worth noting that patients rendered tolerant as a result of a protocol specifically designed to promote tolerance (ITN010 and ITN036) displayed B cell profiles consistent with spontaneously tolerant kidney transplant recipients. This implies that a predictive tool, if identified, might be used to monitor patients in protocols designed to induce tolerance. It would not be unexpected that the proportion of tolerant patients in these protocols would be much larger than in the group of kidney transplant recipients who spontaneously develop tolerance. Indeed, despite the success of tolerance-induction regimens in a significant proportion of the patients, immunologic failures have occurred with each protocol. This highlights our need to identify biomarkers that can be used to identify or predict tolerance as a means to individualize therapy.

Acknowledgments
This research was performed as a project of the Immune Tolerance Network (NIH N01 AI15416 and UM1 AI-109565), an international clinical research consortium headquartered at the Benaroya Research Institute and supported by the National Institute of Allergy and Infectious Diseases. We thank the many clinicians, staff, and particularly the patients, who participated in the clinical trials that made this study possible.

Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

References
Newell et al


Supporting Information

Additional Supporting Information may be found in the online version of this article.

Figure S1: Technical reproducibility of Sequenom analysis. The same RNA samples were tested in 2009 and 2011 using Sequenom technology. Fresh reagents were used in 2011, but the same 226 gene multiplex structure was maintained. The difference between tolerant (TOL) and standard immunosuppression (SI) samples is clearly reproducible for both IGKV1D-13 and IGLL-1. However, the absolute values are not maintained. https://www.itntrialshare.org/FACTOR_figS1.url.

Figure S2: Hierarchical clustering using Euclidean distance measure showing the top 20 genes differentially expressed between tolerant, new tolerant, and standard immunosuppression participants by t-test with False Discovery Rate correction. (p-value < 0.05, **p-value < 0.005, ***p-value < 0.001). White or blank cells show values not available due to assay limitations. Fifteen of the 20 genes are B cell specific, the exceptions being RASGRP1, PPAPDC1B, TUBB2A, TNFAIP6, and CALML4. https://www.itntrialshare.org/FACTOR_figS2.url.

Table S1: ITN057, ITN013, ITN010, and ITN036 participant specimens analyzed for gene expression, flow cytometry, and B cell–activating factor (BAFF) levels analysis.

Table S2: Two hundred thirty-two genes of interest tested by gene expression (including six housekeeping genes).

Table S3: Intersection of statistically significant genes comparing standard immunosuppression (SI) versus tolerant (TOL) in the current experiment and Newell KA et al, J Clin Invest 2010.